TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascletis Pharma, Inc. ( (HK:1672) ) has provided an announcement.
Ascletis Pharma Inc. has announced the selection of its first oral GLP-1R/GIPR/GCGR triple peptide agonist, ASC37, for clinical development. This drug candidate, developed using Ascletis’ proprietary technologies, has shown significantly higher bioavailability and potency compared to existing formulations in non-human primate studies. The company plans to submit an Investigational New Drug Application to the U.S. FDA in 2026, marking a significant step in addressing unmet needs in obesity treatment and strengthening Ascletis’ position in the pharmaceutical industry.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company focused on developing innovative treatments for metabolic diseases, including obesity. The company utilizes proprietary technologies such as Peptide Oral Transport ENhancement Technology (POTENT) and Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) to create a diverse pipeline of drug candidates.
Average Trading Volume: 7,160,322
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.61B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.